Stock Chart
Stock Chart
Citius Pharmaceuticals, Inc.(CTXR)
NASDAQ
$0.9
0.009(1.01%)
CTXR Company Profile
11 Commerce DriveCranford, NJ 07016
1.908.967.6677
http://www.citiuspharma.com
Sector: Health Technology
Industry: Pharmaceuticals: Major
Full Time Employees: 9
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
- Previous Close0.891
- Open0.8925
- Bid0
- Ask0
- Day's Range0.892 - 0.98
- 52 week Range0.4 - 1.5
- Volume5194426
- Avg. Volume1855350
- Market Cap40668210
- Beta (5Y Monthly)0.8925
- PE Ratio (TTM)-1.41
- EPS (TTM)0
- Earnings Date0.8925
- Forward Dividend & Yield0.8925
- Ex-Dividend Date5235495
- 1y Target Est0.8925
KEEP ME INFORMED ON CTXR UPDATES
CTXR Performance
- 5 Day2.4138%1 Month-2.0879%3 Month32.9851%YTD-10.0908%1 Year-23.1897%
CTXR on Twitter
- Tue, Jun 2, 6:41 pm
- Tue, Jun 2, 5:12 pm
- Tue, Jun 2, 4:55 pm
- Tue, Jun 2, 4:50 pm
- Tue, Jun 2, 4:39 pm
- Tue, Jun 2, 12:33 pm
- Tue, Jun 2, 11:53 am
- Tue, Jun 2, 10:52 am
- Tue, Jun 2, 10:51 am
- Tue, Jun 2, 10:22 am
- Tue, Jun 2, 10:17 am
- Tue, Jun 2, 10:11 am
- Tue, Jun 2, 10:11 am
- Tue, Jun 2, 10:07 am
- Tue, Jun 2, 10:00 am
CTXR on iHub
- Thu, May 14, 11:46 am
- Tue, Apr 28, 5:39 pm
- Tue, Apr 28, 1:41 pm
- Tue, Apr 28, 12:27 pm
- Tue, Apr 28, 10:36 am
- Thu, Apr 23, 11:46 am
- Sat, Apr 11, 12:14 am
- Thu, Apr 2, 9:43 am
- Thu, Apr 2, 6:34 am
- Wed, Apr 1, 10:33 pm
- Wed, Apr 1, 4:40 pm
- Wed, Apr 1, 4:05 pm
- Wed, Apr 1, 3:43 pm
- Wed, Apr 1, 3:41 pm
- Wed, Apr 1, 3:40 pm
- Wed, Apr 1, 3:38 pm
- Wed, Apr 1, 3:38 pm
- Wed, Apr 1, 3:32 pm
- Wed, Apr 1, 3:27 pm
- Wed, Apr 1, 3:26 pm
- Wed, Apr 1, 3:24 pm
- Wed, Apr 1, 3:22 pm
- Wed, Apr 1, 3:21 pm
- Wed, Apr 1, 3:17 pm
- Wed, Apr 1, 12:03 pm
- Wed, Apr 1, 11:35 am
- Wed, Apr 1, 11:19 am
- Wed, Apr 1, 11:18 am
- Wed, Apr 1, 11:15 am
- Wed, Apr 1, 11:10 am
- Wed, Apr 1, 11:05 am
- Wed, Apr 1, 8:37 am
- Wed, Apr 1, 8:23 am
- Wed, Apr 1, 8:19 am
- Wed, Apr 1, 8:10 am
- Wed, Mar 11, 10:17 am
- Wed, Mar 11, 10:15 am
- Wed, Mar 11, 10:13 am
- Wed, Mar 11, 10:12 am
- Wed, Mar 11, 9:35 am
- Wed, Mar 4, 12:18 pm
- Wed, Mar 4, 10:56 am
- Tue, Feb 25, 1:43 pm
- Mon, Feb 17, 12:30 am
- Mon, Feb 10, 3:12 am
- Fri, Feb 7, 1:24 pm
- Fri, Feb 7, 6:10 am
- Wed, Feb 5, 10:46 am
- Tue, Feb 4, 12:39 pm
- Wed, Jan 29, 4:54 pm
CTXR News
- Tue, Jun 2, 9:30 am
Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
- Tue, May 26, 8:15 am
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
- Mon, May 18, 2:30 pm
Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- Fri, May 15, 6:49 am
Should You Be Concerned About Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Historical Volatility?
- Thu, May 14, 9:00 am
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- Wed, May 13, 8:15 am
Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Tue, May 12, 8:00 am
Citius Pharmaceuticals Issues May 2020 Shareholder Letter
- Mon, Apr 27, 9:30 am
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
- Wed, Apr 1, 8:07 am
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
- Thu, Mar 26, 9:06 am
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
- Wed, Mar 18, 9:46 am
Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit
- Mon, Mar 16, 6:22 am
Here's Why We Worry About Citius Pharmaceuticals's (NASDAQ:CTXR) Cash Burn Situation
- Tue, Mar 3, 4:45 pm
Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City
- Wed, Feb 26, 8:00 am
Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference
- Tue, Feb 25, 8:00 am
Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok®
- Mon, Feb 10, 8:28 am
Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference
- Tue, Feb 4, 8:00 am
Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
- Mon, Feb 3, 8:00 am
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
- Mon, Jan 27, 8:00 am
Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses
- Thu, Dec 19, 8:00 am
Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial
- */
marketexclusive 
MAISA 
yuzhu 
BioPharmCatalyst 
Fintel.io 
IPHawk 
OTC Dynamics, Inc. 
David 
rob_tradez 💸 
Trash Trader 
Sarah Katilyn 
Pobphorn R 
Private Suite Network | John Cutler 
freddy leon